San Francisco’s FibroGen has poached senior Eli Lilly player Enrique Conterno as its new CEO and member of the Board of Directors.
At Eli Lilly, Mr Conterno served as Senior Vice President, President of Lilly US and Lilly Diabetes, and as a member of the company’s corporate executive committee.
He replaces Jim Schoeneck who served as interim CEO since August 2019 following the passing of founder and long-term CEO, Tom Neff.
Mr Schoeneck has now been appointed to the role of Chairman of the Board of Directors and will continue to serve the company during a transition period as Interim President.
“Following a comprehensive search, we are confident Enrique is the right individual to assume leadership of FibroGen at this pivotal time,” said Tom Kearns, previously Chairman of the Board, and lead Independent Director.
He added: “Enrique re-established Lilly’s leadership position in diabetes, growing the business from approximately $3 billion to over $10 billion in annual revenue.
“Enrique is extremely qualified to lead FibroGen as we prepare for the global commercialisation of roxadustat and continue the advancement of our clinical programs.”